As many as the street believes Alan has! Setting aside the baiting your post clearly intend, I was merely offering my opinion relative the the question posed. I'm eager for Hikma sales to roll in eventually during 2015. As you may recall, I was one of the very few who said we'd not see anything significant in 2014 rolling in for this "rapid ramp." Of course, we are even further away from Lovenox sales. So that leaves us with very little in the short term other than the pipe dream of all of those aces with millions in up front fees. My only point was/is that the prospect for landing the Alirocumab deal seems to be slipping away. If you disagree, why not say so. Maybe offer some points as to why you think we have a great shot even though there has been no FDA application filed.
UNS Price at posting:
57.0¢ Sentiment: Hold Disclosure: Held
